Multicomponent Language Treatment for Primary Progressive Aphasia

N/A

Waitlist Available

Led By Maya L Henry, PhD

Research Sponsored by University of Texas at Austin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must not have

Significant, uncorrected visual or hearing impairment that would interfere with participation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post-treatment (approximately 6-12 weeks after treatment onset)

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to help individuals with Primary Progressive Aphasia (PPA), a condition that causes a gradual decline in communication skills due to brain degeneration. The researchers want to test a new treatment approach

Who is the study for?

This trial is for adults diagnosed with Primary Progressive Aphasia (PPA) who can still score at least 10 on the Mini-Mental State Examination. They must have a partner to attend sessions with them. It's not suitable for those with major visual/hearing issues, other cognitive/behavioral/motor impairments, or additional neurological/psychiatric conditions affecting language skills.

What is being tested?

The study tests three treatments: Multi-LRT focuses on word finding strategies; Multi-VISTA uses video scripts to improve speech; and Multi-CPT involves partners in communication training. The goal is to see if these combined approaches help maintain language functions and quality of life in PPA patients.

What are the potential side effects?

Since this trial involves behavioral interventions like language training rather than medication, traditional side effects are not expected. However, participants may experience fatigue or frustration during therapy sessions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have major vision or hearing problems that would affect my participation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from pre-treatment to post-treatment (approximately 6-12 weeks after treatment onset) and follow-ups at 3 months post-treatment for reporting.